MRKR
Marker Therapeutics
$1.22
$0.00 (0%)Jul 27, 2026
Key metrics
The numbers that frame MRKR today
- Market cap
- $20.34M
- P/E (TTM)
- -1.9
- EV / FCF
- -0.6
- Gross margin
- 100%
- EV / Sales
- 1.5
- ROIC
- 1,100.2%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $0.81
- 52wk High
- $2.46
Growth
Revenue and earnings trend for MRKR
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about MRKR
Is Marker Therapeutics a good buy?
No. Marker Therapeutics has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks mixed. The support signal is useful, but not decisive. We think Marker Therapeutics is selling at a very high price.
What is the market capitalization of MRKR?
Marker Therapeutics's market capitalization is $20.34M.
What is the P/E ratio for MRKR stock?
Marker Therapeutics's current P/E ratio is -1.9.
What is the 52-week high for MRKR stock?
The 52-week high for Marker Therapeutics is $2.46. The current close of $1.22 is 50.4% below that high.
What is the 52-week low for MRKR stock?
The 52-week low for Marker Therapeutics is $0.81. The current close of $1.22 is 50.6% above that low.
Does MRKR stock pay dividends?
Marker Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for MRKR?
Marker Therapeutics's Debt / Equity ratio is 0.